HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS WITH NON-SURGICAL AND POST-SURGICAL HYPOPARATHYROIDISM: A REAL-WORLD CLAIMS ANALYSIS
Author(s)
Tariq Ahmad, MD1, Kelly Roszko, MD, PhD2, Nipith Charoenngam, MD3, Joanna Harton, PhD4, Sonia Kim, MSc4, Lyndsay Smith, PhD5, Arun Mathew, PharmD5, Caroline Geiger, PhD5, Heather Falvey, MSc5.
1University of California San Francisco, Benioff Children’s Hospital, Oakland, CA, USA, 2Mineral Homeostasis Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA, 3Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, 4Genesis Research Group, Hoboken, NJ, USA, 5BridgeBio Pharma, Inc., San Francisco, CA, USA.
1University of California San Francisco, Benioff Children’s Hospital, Oakland, CA, USA, 2Mineral Homeostasis Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA, 3Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, 4Genesis Research Group, Hoboken, NJ, USA, 5BridgeBio Pharma, Inc., San Francisco, CA, USA.
OBJECTIVES: Hypoparathyroidism (hypoPT), a rare endocrine disorder of surgical, genetic, autoimmune or idiopathic origin, is associated with hypocalcaemia, renal complications and substantial morbidity. Real-world evidence on non-surgical hypoPT burden in the USA remains limited. We evaluated healthcare resource utilization (HCRU) and costs among patients with non‑surgical hypoPT, post‑surgical hypoPT and without hypoPT.
METHODS: Using the Optum Market Clarity® database, patients aged ≥16 years with non‑surgical hypoPT, post‑surgical hypoPT or without hypoPT were identified between 01/01/2017 and 31/05/2025. Patients without hypoPT were selected using 1:5 exact age- and sex-matching. Complications, HCRU and costs were evaluated after first hypoPT diagnosis or a randomly selected non-hypoPT qualifying visit (index date), adjusting for demographic differences using inverse odds weights to estimate the average treatment effect on the treated (ATT).
RESULTS: This analysis included 2353 patients with non‑surgical hypoPT, 2327 with post‑surgical hypoPT and 11,765 without hypoPT. Before weighting, the non‑surgical hypoPT cohort was older than the post-surgical hypoPT cohort and included a higher proportion of males and patients with baseline Charlson Comorbidity Index ≥3 (58.6% vs 41.3%). During follow-up (median: 1.7-2.4 years), patients with non-surgical hypoPT had higher rates of complications versus those with post-surgical hypoPT and without hypoPT, including chronic kidney disease (CKD; ATT-weighted mean CKD claims, 39.0 vs 6.3 and 0.6 per patient per year [PPPY]). Patients with non-surgical hypoPT had higher HCRU and costs during follow-up than those with post-surgical hypoPT and without hypoPT (ATT-weighted mean visits PPPY: emergency department, 1.4 vs 1.1 and 0.4; inpatient, 0.7 vs 0.4 and 0.2; outpatient/other, 83.9 vs 46.5 and 21.1; total costs PPPY: $88,157 vs $43,730 and $15,849).
CONCLUSIONS: Complications, HCRU and costs were substantially higher among patients with non‑surgical hypoPT versus post‑surgical hypoPT and without hypoPT. High CKD rates may reflect the heterogeneous etiologies of non‑surgical hypoPT, including syndromic conditions, and/or longer pre-diagnosis cumulative disease exposure.
METHODS: Using the Optum Market Clarity® database, patients aged ≥16 years with non‑surgical hypoPT, post‑surgical hypoPT or without hypoPT were identified between 01/01/2017 and 31/05/2025. Patients without hypoPT were selected using 1:5 exact age- and sex-matching. Complications, HCRU and costs were evaluated after first hypoPT diagnosis or a randomly selected non-hypoPT qualifying visit (index date), adjusting for demographic differences using inverse odds weights to estimate the average treatment effect on the treated (ATT).
RESULTS: This analysis included 2353 patients with non‑surgical hypoPT, 2327 with post‑surgical hypoPT and 11,765 without hypoPT. Before weighting, the non‑surgical hypoPT cohort was older than the post-surgical hypoPT cohort and included a higher proportion of males and patients with baseline Charlson Comorbidity Index ≥3 (58.6% vs 41.3%). During follow-up (median: 1.7-2.4 years), patients with non-surgical hypoPT had higher rates of complications versus those with post-surgical hypoPT and without hypoPT, including chronic kidney disease (CKD; ATT-weighted mean CKD claims, 39.0 vs 6.3 and 0.6 per patient per year [PPPY]). Patients with non-surgical hypoPT had higher HCRU and costs during follow-up than those with post-surgical hypoPT and without hypoPT (ATT-weighted mean visits PPPY: emergency department, 1.4 vs 1.1 and 0.4; inpatient, 0.7 vs 0.4 and 0.2; outpatient/other, 83.9 vs 46.5 and 21.1; total costs PPPY: $88,157 vs $43,730 and $15,849).
CONCLUSIONS: Complications, HCRU and costs were substantially higher among patients with non‑surgical hypoPT versus post‑surgical hypoPT and without hypoPT. High CKD rates may reflect the heterogeneous etiologies of non‑surgical hypoPT, including syndromic conditions, and/or longer pre-diagnosis cumulative disease exposure.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE104
Topic
Economic Evaluation, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Rare & Orphan Diseases